Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

1.60
-0.0300-1.84%
Volume:1.38M
Turnover:2.26M
Market Cap:159.64M
PE:-4.24
High:1.68
Open:1.65
Low:1.60
Close:1.63
Loading ...

Senate Republicans Seek to Protect NASA Programs Targeted for Cuts -- 2nd Update

Dow Jones
·
Yesterday

Sellas Life Sciences expands SAB with Philip Amrein, Alex Kentsis

TIPRANKS
·
05 Jun

Sellas Life Sciences Expands Scientific Advisory Board With Addition of Two World-Renowned Hematology and Oncology Experts

THOMSON REUTERS
·
05 Jun

Press Release: SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Dow Jones
·
05 Jun

Director Jane Wasman Reports Acquisition of Common Shares in Sellas Life Sciences Group Inc

Reuters
·
03 Jun

Director Katherine Bach Kalin Acquires Common Shares of Sellas Life Sciences Group Inc

Reuters
·
23 May

Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study

MT Newswires Live
·
15 May

Sellas Life Sciences Announces First Pediatric Aml Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R Aml

THOMSON REUTERS
·
15 May

Sellas Life Sciences Group Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

SELLAS Life Sciences Gr Q1 EPS $(0.07) Beats $(0.10) Estimate

Benzinga
·
14 May

SELLAS Life Sciences Q1 Net Income USD -5.813 Million

Reuters
·
14 May

SELLAS Life Sciences Reports Q1 2025 Net Loss of $5.8M; EPS Improves to $0.07 from $0.21 Loss in Prior Year

Reuters
·
14 May

Sellas Life Sciences Q1 Operating Income USD -6.063 Million

THOMSON REUTERS
·
14 May

Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
14 May

Sellas Life Sciences Group Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
09 May

Sims Says SLS Segment on Track to Deliver About AU$30 Million Earnings in Fiscal 2025

MT Newswires Live
·
07 May

Lockheed Martin Completes Orion Development for Artemis II Mission to the Moon

PR Newswire
·
02 May

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

GlobeNewswire
·
28 Apr

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
23 Apr

Turnium Technology Group Achieves Cross-Selling Milestone with Claratti and SLS Advisory

TIPRANKS
·
15 Apr